Pathological evolution of hepatitis C virus-"Healthy carriers". Sobesky, R., Lebray, P., Nalpas, B., Vallet-Pichard, A., Fontaine, H., Lagneau, J. L., & Pol, S. World J Gastroenterol, 14(24):3861–5, June, 2008. abstract bibtex AIM: To determine factors associated with fibrosis progression in hepatitis C virus (HCV)-infected patients without significant initial pathological lesions. METHODS: Seventy six untreated HCV-infected patients with initially normal liver as defined by a Knodell score \textless or = 3, with 2 liver biopsies and detectable HCV-RNA were included. Markers of fibrosis progression were assessed. RESULTS: Median duration of infection and time between paired biopsies was 13 (95% CI: 1-28) and 4 (95% CI: 2-16) years respectively. Alanine-transaminase (ALT) activity was normal in 43.4% of cases. 50% demonstrated progression of the necro-inflammation and 34% of fibrosis after a median time evolution of 4 years (95% CI: 2-16). The median difference in the necro-inflammation and fibrosis score between biopsies was low, 1.5 and 0.0 respectively. Univariate analysis showed there was no difference between fibrosis activity or evolution according to genotype or viral load. A higher fibrosis progression (P = 0.03) was observed in patients with body mass index (BMI) \textgreater 25. Fibrosis progression correlated with the time interval between biopsies (P = 0.01). A significant progression of activity (1.7 vs 0.4, P \textless 0.05) or fibrosis (0.9 vs 0.0, P \textless 0.01) was observed in patients with elevated ALT. There was a significant correlation between activity progression and fibrosis progression (P = 0.003). Multivariate analysis demonstrated that fibrosis progression was associated with elevated ALT, BMI \textgreater 25 and the time interval between 2 biopsies. CONCLUSION: There is no fibrosis progression in 66% of patients without significant initial histopathological lesion. Fibrosis progression is associated with elevated ALT and BMI \textgreater 25.
@article{sobesky_pathological_2008,
title = {Pathological evolution of hepatitis {C} virus-"{Healthy} carriers"},
volume = {14},
issn = {1007-9327 (PRINT); 1007-9327 (LINKING)},
shorttitle = {Pathological evolution of hepatitis {C} virus-"{Healthy} carriers"},
abstract = {AIM: To determine factors associated with fibrosis progression in hepatitis C virus (HCV)-infected patients without significant initial pathological lesions. METHODS: Seventy six untreated HCV-infected patients with initially normal liver as defined by a Knodell score {\textless} or = 3, with 2 liver biopsies and detectable HCV-RNA were included. Markers of fibrosis progression were assessed. RESULTS: Median duration of infection and time between paired biopsies was 13 (95\% CI: 1-28) and 4 (95\% CI: 2-16) years respectively. Alanine-transaminase (ALT) activity was normal in 43.4\% of cases. 50\% demonstrated progression of the necro-inflammation and 34\% of fibrosis after a median time evolution of 4 years (95\% CI: 2-16). The median difference in the necro-inflammation and fibrosis score between biopsies was low, 1.5 and 0.0 respectively. Univariate analysis showed there was no difference between fibrosis activity or evolution according to genotype or viral load. A higher fibrosis progression (P = 0.03) was observed in patients with body mass index (BMI) {\textgreater} 25. Fibrosis progression correlated with the time interval between biopsies (P = 0.01). A significant progression of activity (1.7 vs 0.4, P {\textless} 0.05) or fibrosis (0.9 vs 0.0, P {\textless} 0.01) was observed in patients with elevated ALT. There was a significant correlation between activity progression and fibrosis progression (P = 0.003). Multivariate analysis demonstrated that fibrosis progression was associated with elevated ALT, BMI {\textgreater} 25 and the time interval between 2 biopsies. CONCLUSION: There is no fibrosis progression in 66\% of patients without significant initial histopathological lesion. Fibrosis progression is associated with elevated ALT and BMI {\textgreater} 25.},
number = {24},
journal = {World J Gastroenterol},
author = {Sobesky, R. and Lebray, P. and Nalpas, B. and Vallet-Pichard, A. and Fontaine, H. and Lagneau, J. L. and Pol, S.},
month = jun,
year = {2008},
keywords = {Viral/blood Severity of Illness Index Viral Load},
pages = {3861--5},
}
Downloads: 0
{"_id":"FBd4ZNnPNs7w6YNt6","bibbaseid":"sobesky-lebray-nalpas-valletpichard-fontaine-lagneau-pol-pathologicalevolutionofhepatitiscvirushealthycarriers-2008","author_short":["Sobesky, R.","Lebray, P.","Nalpas, B.","Vallet-Pichard, A.","Fontaine, H.","Lagneau, J. L.","Pol, S."],"bibdata":{"bibtype":"article","type":"article","title":"Pathological evolution of hepatitis C virus-\"Healthy carriers\"","volume":"14","issn":"1007-9327 (PRINT); 1007-9327 (LINKING)","shorttitle":"Pathological evolution of hepatitis C virus-\"Healthy carriers\"","abstract":"AIM: To determine factors associated with fibrosis progression in hepatitis C virus (HCV)-infected patients without significant initial pathological lesions. METHODS: Seventy six untreated HCV-infected patients with initially normal liver as defined by a Knodell score \\textless or = 3, with 2 liver biopsies and detectable HCV-RNA were included. Markers of fibrosis progression were assessed. RESULTS: Median duration of infection and time between paired biopsies was 13 (95% CI: 1-28) and 4 (95% CI: 2-16) years respectively. Alanine-transaminase (ALT) activity was normal in 43.4% of cases. 50% demonstrated progression of the necro-inflammation and 34% of fibrosis after a median time evolution of 4 years (95% CI: 2-16). The median difference in the necro-inflammation and fibrosis score between biopsies was low, 1.5 and 0.0 respectively. Univariate analysis showed there was no difference between fibrosis activity or evolution according to genotype or viral load. A higher fibrosis progression (P = 0.03) was observed in patients with body mass index (BMI) \\textgreater 25. Fibrosis progression correlated with the time interval between biopsies (P = 0.01). A significant progression of activity (1.7 vs 0.4, P \\textless 0.05) or fibrosis (0.9 vs 0.0, P \\textless 0.01) was observed in patients with elevated ALT. There was a significant correlation between activity progression and fibrosis progression (P = 0.003). Multivariate analysis demonstrated that fibrosis progression was associated with elevated ALT, BMI \\textgreater 25 and the time interval between 2 biopsies. CONCLUSION: There is no fibrosis progression in 66% of patients without significant initial histopathological lesion. Fibrosis progression is associated with elevated ALT and BMI \\textgreater 25.","number":"24","journal":"World J Gastroenterol","author":[{"propositions":[],"lastnames":["Sobesky"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Lebray"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Nalpas"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Vallet-Pichard"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Fontaine"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Lagneau"],"firstnames":["J.","L."],"suffixes":[]},{"propositions":[],"lastnames":["Pol"],"firstnames":["S."],"suffixes":[]}],"month":"June","year":"2008","keywords":"Viral/blood Severity of Illness Index Viral Load","pages":"3861–5","bibtex":"@article{sobesky_pathological_2008,\n\ttitle = {Pathological evolution of hepatitis {C} virus-\"{Healthy} carriers\"},\n\tvolume = {14},\n\tissn = {1007-9327 (PRINT); 1007-9327 (LINKING)},\n\tshorttitle = {Pathological evolution of hepatitis {C} virus-\"{Healthy} carriers\"},\n\tabstract = {AIM: To determine factors associated with fibrosis progression in hepatitis C virus (HCV)-infected patients without significant initial pathological lesions. METHODS: Seventy six untreated HCV-infected patients with initially normal liver as defined by a Knodell score {\\textless} or = 3, with 2 liver biopsies and detectable HCV-RNA were included. Markers of fibrosis progression were assessed. RESULTS: Median duration of infection and time between paired biopsies was 13 (95\\% CI: 1-28) and 4 (95\\% CI: 2-16) years respectively. Alanine-transaminase (ALT) activity was normal in 43.4\\% of cases. 50\\% demonstrated progression of the necro-inflammation and 34\\% of fibrosis after a median time evolution of 4 years (95\\% CI: 2-16). The median difference in the necro-inflammation and fibrosis score between biopsies was low, 1.5 and 0.0 respectively. Univariate analysis showed there was no difference between fibrosis activity or evolution according to genotype or viral load. A higher fibrosis progression (P = 0.03) was observed in patients with body mass index (BMI) {\\textgreater} 25. Fibrosis progression correlated with the time interval between biopsies (P = 0.01). A significant progression of activity (1.7 vs 0.4, P {\\textless} 0.05) or fibrosis (0.9 vs 0.0, P {\\textless} 0.01) was observed in patients with elevated ALT. There was a significant correlation between activity progression and fibrosis progression (P = 0.003). Multivariate analysis demonstrated that fibrosis progression was associated with elevated ALT, BMI {\\textgreater} 25 and the time interval between 2 biopsies. CONCLUSION: There is no fibrosis progression in 66\\% of patients without significant initial histopathological lesion. Fibrosis progression is associated with elevated ALT and BMI {\\textgreater} 25.},\n\tnumber = {24},\n\tjournal = {World J Gastroenterol},\n\tauthor = {Sobesky, R. and Lebray, P. and Nalpas, B. and Vallet-Pichard, A. and Fontaine, H. and Lagneau, J. L. and Pol, S.},\n\tmonth = jun,\n\tyear = {2008},\n\tkeywords = {Viral/blood Severity of Illness Index Viral Load},\n\tpages = {3861--5},\n}\n\n\n\n","author_short":["Sobesky, R.","Lebray, P.","Nalpas, B.","Vallet-Pichard, A.","Fontaine, H.","Lagneau, J. L.","Pol, S."],"key":"sobesky_pathological_2008","id":"sobesky_pathological_2008","bibbaseid":"sobesky-lebray-nalpas-valletpichard-fontaine-lagneau-pol-pathologicalevolutionofhepatitiscvirushealthycarriers-2008","role":"author","urls":{},"keyword":["Viral/blood Severity of Illness Index Viral Load"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":["viral/blood severity of illness index viral load"],"search_terms":["pathological","evolution","hepatitis","virus","healthy","carriers","sobesky","lebray","nalpas","vallet-pichard","fontaine","lagneau","pol"],"title":"Pathological evolution of hepatitis C virus-\"Healthy carriers\"","year":2008}